Generic olanzapine: health authority opportunity or nightmare?

References

• Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy, a comparison in seven European countries. Health Policy85, 305–813 (2008).
   PubMed Web of Science ®Google Scholar
• Cook J, Vernon J, Mannin R. Pharmaceuical risk-sharing agreements. Pharmacoeconomics26(7), 551–556 (2008).
   PubMed Web of Science ®Google Scholar
• Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson L. Enhancing the rational use of new medicines across European healthcare systems – Editorial. Eur. J. Clin.Pharmacol.64(12), 1137–1138 (2008).
   PubMed Web of Science ®Google Scholar
• Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med.359(4), 333–335 (2008).
   PubMed Web of Science ®Google Scholar
• Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics26(7), 537–550 (2008).
   PubMed Web of Science ®Google Scholar
• Kusnik-Joinville O, Weill A, Salanave B et al. Prevalence and treatment of diabetes in France, trends between 2000 and 2005. Diabetes Metab.34, 266–272 (2008).
   Google Scholar
• Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res.8(4), 357–371 (2008).
   PubMedGoogle Scholar
• Godman B. Performance measurement and investment decision making – rhetoric versus reality. In: Managed Care. Preuss KJ, Räbiger R, Sommer JH (Eds). Schattauer GmbH, Germany, 201–211 (2002).
   Google Scholar
• Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin.23(11), 2647–2654 (2007).
   PubMed Web of Science ®Google Scholar
• Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev. Clin. Pharmacol.1(4), 497–503 (2008).
   PubMedGoogle Scholar
• Kanavos P. Generic policies, rhetoric vs. reality. Euro Observer10(2), 1–6 (2008).
   Google Scholar
• Duerden M. Making sense of drug pricing. Prescriber supplement (2006). John Wiley & Sons Ltd, Chichester, UK.
   Google Scholar
• Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it, Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics26(2), 91–98 (2008).
   PubMed Web of Science ®Google Scholar
• Chaplin S, Duerdin M. When brands are best – brand vs. generic prescribing. Prescriber Guide Supplement (2006). Printed and published by John Wiley & Sons Ltd, Chichester, UK.
   Google Scholar
• Yu B, Yun SC, Maguire A. Is generic fluoxetine effective? J. Affect. Disord.81, 185–186 (2004).
   PubMedGoogle Scholar
• Van Ameringen M, Mancini C, Patterson B, Bennett M. Symptom relapse following switch from Celexa to generic citalopram, an anxiety disorders case series. J. Psychopharmacol.21(5), 472–476 (2007).
   PubMed Web of Science ®Google Scholar
• Vergouwen A, Bakker A. Adverse effects after switching to a different generic form of paroxetine, paroxetine mesylate instead of paroxetine HCl hemihydrate. Ned. Tijdschr. Geneskd146(17), 811–12 (2002).
   PubMedGoogle Scholar
• Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin. Ther.23, 1720–1731 (2001).
   PubMed Web of Science ®Google Scholar
• Alvarez CA, Mascarenas C, Timmerman I. Increasing psychosis in a patient switched from Clozaril to generic clozapine. Am. J. Psychiatry163 (4), 746 (2006).
   Google Scholar
• Whisky E, Taylor D. Generic clozapine, opportunity or threat? Pharmaceutical J.273, 112 (2004).
   Google Scholar
• Nuss P, Taylor D, De Hert M, Hummer M. The generic alternative in schizophrenia, opportunity or threat? CNS Drugs18 (12), 769–775 (2004)
   Google Scholar
• Healy DJ, Taylor S, Goldman M, Barry K, Blow F, Milner KK. Clinical equivalence of generic clozapine. Community Ment. Health J.41(4), 393–398 (2005).
   PubMedGoogle Scholar
• Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM. Evaluation of an interchangeability switch in patients treated with clozapine, a retrospective review. J. Clin. Psychiatry67(7), 1047–1054 (2006).
   PubMed Web of Science ®Google Scholar
• Paton C. Generic clozapine, outcomes after switching. Br. J. Psychiatry89, 184–185 (2006)
   Google Scholar
• Bazire S, Burton V. Generic clozapine in schizophrenia, what is all the fuss about? Pharmaceutical J.173, 720–721 (2004).
   Google Scholar
• Andretta M, Ciuna A, Corbari L et al. Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy. Soc. Psychiatry Psychiatr. Epidemiol.40, 72–77 (2005).
   PubMedGoogle Scholar
• Knapp M, Kanavos P, King D, Yesudian HM. Economic issues in access to medications, schizophrenia treatment in England. Int. J. Law Psychiatry28, 514–531 (2005).
   Google Scholar
• Mirandola M, Andretta M, Corbari L et al. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population, retrospective database analysis, 1999–2002. Pharmacoepidemiol. Drug Saf.15, 412–420 (2006).
   Google Scholar
• Rosenheck R, Swartz M, McEvoy J et al. Second-generation antispychotics, reviewing the cost–effectiveness component of the CATIE trial. Expert Rev. Pharmacoeconomics Outcomes Res.7(2), 103–111 (2007).
   PubMedGoogle Scholar
• Liu GG, Sun SX, Christensen DB, Luo X. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann. Pharmacother.38, 134–141 (2004).
   PubMed Web of Science ®Google Scholar
• Barbui C, Lintas C, Percudani M. Head-to-head comparison of the cost of atypical antipsychotics – a systematic review. CNS Drugs19 (1), 935–950 (2005).
   Google Scholar
• Paris V. Pharmaceutical regulation in France 1980 – 2003. Int. J. Health Plann. Manage.20, 307–328 (2005).
   PubMed Web of Science ®Google Scholar
• Garattini L, Ghislandi S. Off-patent drugs in Italy, a short sighted view? Eur. J. Health Econ.7, 79–83 (2006).
   PubMedGoogle Scholar
• Seeley E, Kanavos P. Generic medicines from a societal perspective, savings for healthcare systems? Eurohealth14(2), 18–22 (2008).
   Google Scholar
• Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France, is there room for further efficiency savings. Curr. Med. Res. Opin.23, 2467–2476 (2007).
   PubMed Web of Science ®Google Scholar
• Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin.23(1), 105–116 (2007).
   PubMed Web of Science ®Google Scholar
• Frank RG. The ongoing regulation of generic drugs. NEJM357(20), 1993–1996 (2007).
   PubMed Web of Science ®Google Scholar
• van Os S, Relleke M, Piniella PM. Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets. Int. J. Clin. Pharmacol. Ther.45(5), 293–299 (2007).
   PubMed Web of Science ®Google Scholar
• Jack A. Balancing Big Pharma’s books. BMJ336, 418–419 (2008).
   PubMed Web of Science ®Google Scholar